Fort Lauderdale, Fla.-based Broward Health has launched bispecific T-cell engager therapy at its flagship Broward Health Medical Center after training care teams across the hospital to support patients receiving the treatment.
The first patient, who has a form of lung cancer, was treated Oct. 12, according to a Broward Health news release.
Before the launch, nurses, emergency medicine physicians, hospitalists, intensivists, residents, pharmacists and oncology teams underwent specialized training. The hospital established protocols for administering the therapy and monitoring patients, and Broward Health updated its Epic EHR to flag patients receiving the therapy so clinical teams can coordinate their care.
Broward Health plans to expand the therapy to other sites across the system and begin treating additional cancer patients, including those with multiple myeloma.
“Our team has established the infrastructure, protocols and expertise necessary to deliver this therapy safely and effectively,” Simon Blanc, MD, medical director of hematology-oncology at Broward Health Medical Center, said in the release.
Broward Health is one of the 10 largest public health systems in the U.S. and provides more than $523 million in charity and uncompensated care each year.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
